Compare Amylx Pharmaceuticals Inc (AMLX) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Endeavour Silver Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.64B), while Endeavour Silver Corp trades at $10.84 (market cap $3.14B). The key difference: Endeavour Silver Corp is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals.
| AMLX | EXK | |
|---|---|---|
Market Cap | $2.64B | $3.14B |
Sector | Health | Basic Materials |
52-Week High | $24.19 | $14.12 |
52-Week Low | $7.82 | $5.31 |
Enterprise Value | $2.39B | $3.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
EXK is trading at $9.54, up 8.04% today, with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with Q2 2026 earnings matching estimates and revenue growth from $468M in 2025 to $737M projected for 2026. Recent news highlights a $25M credit facility and operational expansion at Terronera mine.
Outlook remains positive with analyst consensus price target of $15.50 (62% upside), though risks include volatile earnings history and elevated P/E ratio of 51.2. The stock offers growth potential through silver production expansion but faces commodity price sensitivity and execution risks in mine development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
